- Home
- SBRA vs GH Comparison
SBRA vs GH Comparison
Compare SBRA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- GH
- Stock Information
- Founded
- SBRA 2010
- GH 2011
- Country
- SBRA United States
- GH United States
- Employees
- SBRA N/A
- GH N/A
- Industry
- SBRA Real Estate Investment Trusts
- GH Medical Specialities
- Sector
- SBRA Real Estate
- GH Health Care
- Exchange
- SBRA Nasdaq
- GH Nasdaq
- Market Cap
- SBRA N/A
- GH 4.9B
- IPO Year
- SBRA N/A
- GH 2018
- Fundamental
- Price
- SBRA $18.62
- GH $50.75
- Analyst Decision
- SBRA Buy
- GH Strong Buy
- Analyst Count
- SBRA 7
- GH 20
- Target Price
- SBRA $19.71
- GH $54.35
- AVG Volume (30 Days)
- SBRA 2.6M
- GH 2.1M
- Earning Date
- SBRA 08-06-2025
- GH 08-06-2025
- Dividend Yield
- SBRA 6.45%
- GH N/A
- EPS Growth
- SBRA 185.79
- GH N/A
- EPS
- SBRA 0.60
- GH N/A
- Revenue
- SBRA $720,247,000.00
- GH $773,996,000.00
- Revenue This Year
- SBRA $5.91
- GH $23.14
- Revenue Next Year
- SBRA $5.30
- GH $21.42
- P/E Ratio
- SBRA $31.09
- GH N/A
- Revenue Growth
- SBRA 10.76
- GH 28.20
- 52 Week Low
- SBRA $15.11
- GH $20.14
- 52 Week High
- SBRA $20.03
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- SBRA 60.21
- GH 60.25
- Support Level
- SBRA $18.14
- GH $49.50
- Resistance Level
- SBRA $18.55
- GH $53.42
- Average True Range (ATR)
- SBRA 0.38
- GH 2.19
- MACD
- SBRA 0.01
- GH -0.12
- Stochastic Oscillator
- SBRA 90.66
- GH 54.03
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.